Retinal Update 2020

Edina, MN,  February 1, 2020

*Presentation Outlines will be available at a Later Date

Target Audience

Ophthalmologists, Optometrists, Nursing Personnel, Ophthalmic Technicians,
and Allied Health Personnel.

 

Learning Objectives

  • To understand the mechanism of new general cancer therapies
  • To identify clinical signs of checkpoint inhibitor toxicity
  • To identify clinical signs of MEK inhibitor toxicity
  • To discuss management strategies for DME.
  • To understand the role of PRP laser and anti-VEGF therapy for the current management of PDR.
  • To understand current trends and future strategies for Diabetic Retinopathy management.
  • To understand the current management of pediatric retinal diseases and the pathophysiology underlying pediatric retinal disease
  • To identify common retinal disorders found in the pediatric population
  • To discuss preoperative risk factors of cataract surgery for complications
  • To understand anterior segment intraoperative management of cataract surgery complications
  • To discuss the urgency of referrals following cataract surgery complications
  • To identify the clinical features of exudative retinal detachments
  • To understand the role of laboratory testing in exudative retinal detachment
  • To identify the surgical indication for scleral window surgery
  • To review pentosan polysulfate (Elmiron) maculopathy.
  • To discuss macular edema associated with fingolimod (Gilenya).
  • To review the current hydroxychloroquine (Plaquenil) screening guidelines.
  • To gain a better understanding of the imaging interpretation of toxic retinopathies.
  • To review the phakic and pseudophakic results from the PRO study
  • To review outcomes of the 360 degree laser sub-study of the PRO study
  • To discuss insights from the PIVOT trial – Pneumatic Retinopexy vs. PPV for RRD.
  • To review updates for understanding the pathophysiology for choroidal melanomas.
  • To review updates for assessing choroidal melanomas.
  • To review new developments in treatment choroidal melanomas.

The Westin Edina Galleria

Accommodations:

The Westin Edina Galleria
3201 Galleria Drive
Edina, MN  55435

(952) 567-5000

For discounted rate, please reference “Retinal Update 2020” when booking rooms

Room Block cut-off date is January 20, 2020

Breakfast: 

Coffee and rolls will be available during registration.

 

Brunch:  

A brunch will be served during the break.

Guest Faculty

Prithvi Mruthyunjaya, MD, MHS

Associate Professor of Ophthalmology, Ocular Oncology and Vitreoretinal Surgery
Director, Ocular Oncology Service
Director, Vitreoretinal Surgery Fellowship
Byers Eye Institute at Stanford University

Faculty Members from VitreoRetinal Surgery, PA

Herbert L. Cantrill, MD
Ed Ryan Jr, MD
Sundeep Dev, MD
Polly Quiram, MD, PhD
John Davies, MD
Alex Ringeisen, MD
Peter Tang, MD, PhD

 

Retinal Update 2020

2/1/2020

Disclosure:

It is the policy of the Minnesota Medical Association (MMA) to ensure balance, independence, objectivity, and scientific rigor in its CME activities. To comply with the Standards for Commercial Support of the Accreditation Council for Continuing Medical Education (ACCME), the MMA requires planning committee members and faculty to disclose any relevant financial relationship he/she and his/her spouse/partner has with a commercial interest.

The following financial relationships were disclosed and resolved prior to the activity:

Prithvi Mruthyunjaya

Advisory Board: Aura Biosciences and Castle Biosciences

 

Edwin Ryan Royalties: Alcon Surgical

The remaining members of the faculty and planning committee for this conference have indicated that they have no relevant financial relationships to disclose related to the content of the CME activity. Faculty members have declared that they will uphold the MMA’s standards regarding CME activities and that any clinical recommendations are based on the best available evidence or are consistent with generally accepted medical practice. Please indicate in the comments section of the evaluation form whether you detect any instances of bias toward products manufactured by commercial interests.

CME Credit:

This activity has been planned and implemented in accordance with the accreditation requirements and polices of the Accreditation Council for Continuing Medical Education through the joint providership of the Minnesota Medical Association and the VitreoRetinal Surgery. The Minnesota Medical Association (MMA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Minnesota Medical Association designates this live activity for a maximum of 4 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support:

There is no commercial support for this event.

A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients

The ACCME defines “‘relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

TUITION: 

$100.00 for physicians, nurses, technicians and allied health personnel.

$25.00 for retired physicians.

No charge for residents and fellows.

Fee includes conference materials, continental breakfast, brunch and break refreshments.

For program information, please contact Gretchen Dertz (952) 259-4273.